1. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults
- Author
-
François-Xavier, Blanc, Anani D, Badje, Maryline, Bonnet, Delphine, Gabillard, Eugène, Messou, Conrad, Muzoora, Sovannarith, Samreth, Bang D, Nguyen, Laurence, Borand, Anaïs, Domergue, Delphine, Rapoud, Naome, Natukunda, Sopheak, Thai, Sylvain, Juchet, Serge P, Eholié, Stephen D, Lawn, Serge K, Domoua, Xavier, Anglaret, Didier, Laureillard, Thi Hai Ly, Tran, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Department of Medicine, Harvard Medical School [Boston] (HMS), emlyon business school, Unité d'Épidémiologie et de Santé Publique [Phnom Penh], Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Réseau International des Instituts Pasteur (RIIP), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Programme PAC-CI, Centre Hospitalier Universitaire [Treichville] (CHU), The Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine, University of Cape Town, ANRS France Recherche Nord & sud Sida-hiv hépatites, and Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Tuberculosis ,[SDV]Life Sciences [q-bio] ,Antitubercular Agents ,HIV Infections ,030204 cardiovascular system & hematology ,law.invention ,IDLIC ,Immunocompromised Host ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Tuberculosis diagnosis ,law ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,Ethambutol ,ComputingMilieux_MISCELLANEOUS ,Bacterial disease ,AIDS-Related Opportunistic Infections ,business.industry ,Hazard ratio ,HIV ,Bacterial Infections ,General Medicine ,Viral Load ,Pyrazinamide ,medicine.disease ,CD4 Lymphocyte Count ,3. Good health ,Anti-Retroviral Agents ,Female ,business ,medicine.drug - Abstract
Background In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mortality after ART initiation is high in these patients, and tuberculosis and invasive bacterial diseases are common causes of death. Methods We conducted a 48-week trial of empirical treatment for tuberculosis as compared with treatment guided by testing in HIV-infected adults who had not previously received ART and had CD4+ T-cell counts below 100 cells per cubic millimeter. Patients recruited in Ivory Coast, Uganda, Cambodia, and Vietnam were randomly assigned in a 1:1 ratio to undergo screening (Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography) to determine whether treatment for tuberculosis should be started or to receive systematic empirical treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months. The primary end point was a composite of death from any cause or invasive bacterial disease within 24 weeks (primary analysis) or within 48 weeks after randomization. Results A total of 522 patients in the systematic-treatment group and 525 in the guided-treatment group were included in the analyses. At week 24, the rate of death from any cause or invasive bacterial disease (calculated as the number of first events per 100 patient-years) was 19.4 with systematic treatment and 20.3 with guided treatment (adjusted hazard ratio, 0.95; 95% confidence interval [CI], 0.63 to 1.44). At week 48, the corresponding rates were 12.8 and 13.3 (adjusted hazard ratio, 0.97 [95% CI, 0.67 to 1.40]). At week 24, the probability of tuberculosis was lower with systematic treatment than with guided treatment (3.0% vs. 17.9%; adjusted hazard ratio, 0.15; 95% CI, 0.09 to 0.26), but the probability of grade 3 or 4 drug-related adverse events was higher with systematic treatment (17.4% vs. 7.2%; adjusted hazard ratio 2.57; 95% CI, 1.75 to 3.78). Serious adverse events were more common with systematic treatment. Conclusions Among severely immunosuppressed adults with HIV infection who had not previously received ART, systematic treatment for tuberculosis was not superior to test-guided treatment in reducing the rate of death or invasive bacterial disease over 24 or 48 weeks and was associated with more grade 3 or 4 adverse events. (Funded by the Agence Nationale de Recherches sur le Sida et les Hepatites Virales; STATIS ANRS 12290 ClinicalTrials.gov number, NCT02057796.).
- Published
- 2020
- Full Text
- View/download PDF